Suggestions
Till Bruckner
Founder of TranspariMED and Research Fellow at QUEST
Till Bruckner is a professional with a relevant PhD in Politics focusing on the accountability of international aid from the University of Bristol and an MSc in International Relations from the University of Wales, Aberystwyth.
With over two decades of work experience, Till has been involved in various roles such as a Research Fellow at the Berlin Institute of Health, Founder of TranspariMED, and Advocacy Manager at Transparify.
Till Bruckner has also contributed to organizations like Sense about Science as an AllTrials Monitoring Adviser, Transparency International Georgia as an Aid Monitoring Coordinator, and Catholic Relief Services as a Field Worker.
Moreover, he has shared his expertise as a University Tutor at the University of Bristol, a Researcher and Project Developer at Business and Finance Consulting (BFC), and held the position of Long-term Consultant at CARE International in the Caucasus.
Till's professional journey includes experiences in public relations, journalism, consulting, and education, highlighting his diverse skill set and knowledge across different domains.
His career reflects a strong focus on evidence-based advocacy, showcasing a commitment to influencing positive change and ensuring transparency and accountability in various sectors.
Till Bruckner's extensive background and involvement in impactful initiatives demonstrate his dedication to making a difference through his work and expertise in the field of international relations and aid accountability.
Highlights
Victory for patients: EMA will no longer allow pharma companies to keep clinical trial protocols secret. In future, study protocols will be made public the moment a trial is approved. Until previous plans, pharma companies could ‘defer’ the publication of study protocols for several years after trial completion. The new transparency rules will allow health technology assessment bodies, guideline developers and independent researchers to better determine which medicines should be offered to what patient groups. EMA’s change in approach follows advocacy by TranspariMED, Revue Prescrire and several other health groups. Please help TranspariMED to win more victories for patients and science by making a small monthly donation to support our work. Full story here: https://lnkd.in/dSmxa8qf
The UK government will introduce a legal requirement to make public the results of all clinical trials within 12 months of trial completion. Any company or university breaking the law will be refused permission to start new trials, the UK drug regulator announced on Tuesday.
In addition, the new law will make it mandatory to pre-register trials and to share their outcomes with participants.
The new legislative agenda follows a public consultation in which the over 2,000 respondents overwhelmingly supported new legislation to require trial registration (97%), rapid results reporting (94%), and sharing of trial findings with participants (91%).
The UK law sets a new global benchmark for transparency in medical research. Comparable disclosure laws in the European Union and the United States only cover some types of trials, and so far remain unenforced.
This is a major victory for patients in the UK and sets a new global gold standard for transparency.
https://lnkd.in/dgYCTbSf
